JP2002518347A5 - - Google Patents

Download PDF

Info

Publication number
JP2002518347A5
JP2002518347A5 JP2000554401A JP2000554401A JP2002518347A5 JP 2002518347 A5 JP2002518347 A5 JP 2002518347A5 JP 2000554401 A JP2000554401 A JP 2000554401A JP 2000554401 A JP2000554401 A JP 2000554401A JP 2002518347 A5 JP2002518347 A5 JP 2002518347A5
Authority
JP
Japan
Prior art keywords
shows
antibodies
val
psa
prt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000554401A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002518347A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB1999/001115 external-priority patent/WO1999065523A1/en
Publication of JP2002518347A publication Critical patent/JP2002518347A/ja
Publication of JP2002518347A5 publication Critical patent/JP2002518347A5/ja
Pending legal-status Critical Current

Links

JP2000554401A 1998-06-15 1999-06-15 前立腺癌治療のための免疫療法組成物および方法 Pending JP2002518347A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8928198P 1998-06-15 1998-06-15
US60/089,281 1998-06-15
PCT/IB1999/001115 WO1999065523A1 (en) 1998-06-15 1999-06-15 Immunotherapeutic composition and method for the treatment of prostate cancer

Publications (2)

Publication Number Publication Date
JP2002518347A JP2002518347A (ja) 2002-06-25
JP2002518347A5 true JP2002518347A5 (https=) 2007-01-18

Family

ID=22216751

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000554401A Pending JP2002518347A (ja) 1998-06-15 1999-06-15 前立腺癌治療のための免疫療法組成物および方法

Country Status (9)

Country Link
US (3) US6881405B2 (https=)
EP (1) EP1085905B1 (https=)
JP (1) JP2002518347A (https=)
AT (1) ATE480566T1 (https=)
AU (1) AU768002B2 (https=)
CA (1) CA2328504A1 (https=)
DE (1) DE69942742D1 (https=)
IL (1) IL139700A (https=)
WO (1) WO1999065523A1 (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8038994B2 (en) 1996-05-15 2011-10-18 Quest Pharmatech Inc. Combination therapy for treating disease
IL139700A (en) * 1998-06-15 2005-09-25 Altarex Medical Corp Immunotherapeutic composition for the treatment of prostate cancer
HU226150B1 (en) 1999-01-13 2008-05-28 Igeneon Krebs Immuntherapie Use of antibodies for anticancer vaccination
CA2408547A1 (en) * 2000-05-11 2001-11-15 Altarex Corp. Therapeutic method and composition utilizing antigen-antibody complexation and presentation by dendritic cells
US8658773B2 (en) 2011-05-02 2014-02-25 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
US20050260208A1 (en) * 2002-04-11 2005-11-24 Altarex Medical Corp. Binding agents and their use in targeting tumor cells
AU2003286463A1 (en) * 2002-10-17 2004-05-04 Altarex Medical Corp. Therapeutic adjuvant
US7902338B2 (en) 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
GB0329146D0 (en) * 2003-12-16 2004-01-21 Glaxosmithkline Biolog Sa Vaccine
CA2523032A1 (en) 2005-10-07 2007-04-07 Immunovaccine Technologies Inc. Vaccines for cancer therapy
US20080095790A1 (en) * 2006-10-24 2008-04-24 Perambakam Supriya M Methods of Treating Prostate Cancer
CN106310293A (zh) 2007-09-27 2017-01-11 免疫疫苗技术有限公司 在包括连续疏水相的载体中的脂质体在体内输送多核苷酸中的应用
US20100209452A1 (en) * 2007-10-03 2010-08-19 Immunovaccine Technologies, Inc Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereof
EP2331130B1 (en) * 2008-04-09 2018-02-14 Oncoquest Inc. Ige antibodies for the treatment of cancer
WO2009146523A1 (en) * 2008-06-05 2009-12-10 Immunovaccine Technologies Inc. Compositions comprising liposomes, an antigen, a polynucleotide and a carrier comprising a continuous phase of a hydrophobic substance
GB0811567D0 (en) * 2008-06-24 2008-07-30 Cytosystems Ltd Assay
ES3000111T3 (en) 2009-02-13 2025-02-27 Immunomedics Inc Intermediates for preparing conjugates with an intracellularly-cleavable linkage
US20160095939A1 (en) 2014-10-07 2016-04-07 Immunomedics, Inc. Neoadjuvant use of antibody-drug conjugates
EP2478110B1 (en) 2009-09-16 2016-01-06 Immunomedics, Inc. Class i anti-cea antibodies and uses thereof
ES2978177T3 (es) 2009-12-02 2024-09-06 Immunomedics Inc Combinación de radio inmunoterapia y conjugados anticuerpo-fármaco para mejorar la terapia contra el cáncer
WO2011073215A2 (en) * 2009-12-14 2011-06-23 Immatics Biotechnologies Gmbh Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
CN113876945A (zh) 2011-10-06 2022-01-04 免疫疫苗技术有限公司 包括激活或增加tlr2活性的佐剂的脂质体组合物及其应用
CN104379169A (zh) 2012-08-14 2015-02-25 Ibc药品公司 用于治疗疾病的t-细胞重定向双特异性抗体
WO2017004144A1 (en) 2015-07-01 2017-01-05 Immunomedics, Inc. Antibody-sn-38 immunoconjugates with a cl2a linker
CN107753954A (zh) 2012-12-13 2018-03-06 免疫医疗公司 功效改进且毒性降低的抗体与sn‑38的免疫缀合物的剂量
JP6447933B2 (ja) 2014-02-21 2019-01-09 アイビーシー ファーマスーティカルズ，インコーポレイテッド Ｔｒｏｐ−２発現細胞に対する免疫応答を誘発することによる疾患治療
CA2935748A1 (en) 2014-02-25 2015-09-03 Immunomedics, Inc. Humanized rfb4 anti-cd22 antibody
EP3160504B1 (en) 2014-06-24 2020-09-16 Immunomedics, Inc. Anti-histone therapy for vascular necrosis in severe glomerulonephritis
AU2016252771B2 (en) 2015-04-22 2021-12-16 Immunomedics, Inc. Isolation, detection, diagnosis and/or characterization of circulating Trop-2-positive cancer cells
JP6980980B2 (ja) 2015-06-25 2021-12-15 イミューノメディクス、インコーポレイテッドImmunomedics, Inc. 抗ｈｌａ‐ｄｒまたは抗ｔｒｏｐ‐２抗体と微小管阻害剤、ｐａｒｐ阻害剤、ブルトンキナーゼ阻害剤またはホスホイノシチド３‐キナーゼ阻害剤との併用は癌の治療効果を有意に改善する
WO2022239720A1 (ja) 2021-05-10 2022-11-17 公益財団法人川崎市産業振興財団 抗原への結合親和性を低減させた抗体

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3865689A (en) * 1972-11-09 1975-02-11 Hoffmann La Roche Method of producing carcinoembryonic antigens
US4446122A (en) 1979-12-28 1984-05-01 Research Corporation Purified human prostate antigen
US4331647A (en) * 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US5053224A (en) * 1983-11-07 1991-10-01 Hilary Koprowski Induction of antibody response to solid tumors with anti-idiotype antibodies
WO1987000053A1 (en) 1985-07-05 1987-01-15 Slichter Sherrill J Method of reducing immunogenicity and inducing immunologic tolerance
EP0234122A3 (en) 1986-02-21 1989-03-22 Oncogen Limited Partnership Tumor therapy with biologically active anti-tumor antibodies
NZ222509A (en) 1986-11-19 1993-03-26 Oncogen Hybridoma cell line producing antibodies binding to tumour-associated mucin antigen
US5059680A (en) 1986-11-24 1991-10-22 Centocor, Inc. Method of isolating ca 125 antigen
US5683674A (en) 1987-01-07 1997-11-04 Imperial Cancer Research Technology Ltd. Antibody against human mucin core protein and method of preparing and using same
US4859449A (en) 1987-09-14 1989-08-22 Center For Molecular Medicine And Immunology Modified antibodies for enhanced hepatocyte clearance
GB8728856D0 (en) 1987-12-10 1988-01-27 Bradwell A R Tumour-locating agents & method of locating tumours
AU656716B2 (en) 1989-09-15 1995-02-16 Genetic Systems Corporation Hybridoma CT43 producing a monoclonal antibody to a mucin epitope of colorectal cancer
US5165922A (en) * 1990-05-22 1992-11-24 Bristol-Myers Squibb Company Synergistic tumor therapy with combinations of biologically active anti-tumor antibodies and chemotherapy
DE4133791A1 (de) 1991-10-11 1993-04-15 Behringwerke Ag Monoklonale antikoerper gegen tumorassoziierte antigene, verfahren zu ihrer herstellung und ihre verwendung
EP0652014A1 (en) 1993-11-10 1995-05-10 National Institute Of Immunology Treatment of prostatic hypertrophy
US5773292A (en) 1995-06-05 1998-06-30 Cornell University Antibodies binding portions, and probes recognizing an antigen of prostate epithelial cells but not antigens circulating in the blood
US6143509A (en) 1996-02-06 2000-11-07 Abbott Laboratories Prostate specific antigen peptides and uses thereof
GB9606228D0 (en) 1996-03-25 1996-05-29 Secr Defence Apparatus for matrix coating fibres with metal vapour
AU4086397A (en) * 1996-09-06 1998-03-26 Centocor Inc. Monoclonal antibodies specific for prostate specific antigen and methods of detecting prostate specific antigen
IL139700A (en) * 1998-06-15 2005-09-25 Altarex Medical Corp Immunotherapeutic composition for the treatment of prostate cancer

Similar Documents

Publication Publication Date Title
JP2002518347A5 (https=)
US5869620A (en) Multivalent antigen-binding proteins
HUP0303173A2 (hu) Csökkent immunogenitású, módosított anti-EGFR-ellenanyagok
CA2410604A1 (en) Use of coiled-coil structural scaffold to generate structure-specific peptides
Vichier‐Guerre et al. Induction of carbohydrate‐specific antibodies in HLA‐DR transgenic mice by a synthetic glycopeptide: a potential anti cancer vaccine for human use
CA2249746A1 (en) Porphyromonas gingivalis antigens for the diagnosis and treatment of periodontitis
Losman et al. Baboon anti‐idiotype antibodies mimic a carcinoembryonic antigen epitope
RU2001130068A (ru) Антиидиотипические антитела к антителам, которые ингибируют связывание иммуноглобулина с его высокоаффинным рецептором
JP2003514028A (ja) ワクチンとしての抗体の新たな使用
Reinartz et al. Immunological properties of a single-chain fragment of the anti-idiotypic antibody ACA125
Losman et al. Mimicry of a carcinoembryonic antigen epitope by a rat monoclonal anti‐idiotype antibody
Moritz et al. Micro-sequencing strategies for the human A33 antigen, a novel surface glycoprotein of human gastrointestinal epithelium
JP2007161700A (ja) メラノーマに対する免疫応答を刺激するためのペプチド
EP0957111B1 (en) Specific binding proteins for treating canine allergy
de Moraes et al. Induction of an immune response through the idiotypic network with monoclonal anti‐idiotype antibodies in the carcinoembryonic antigen system
Lehmann et al. Tumor‐antigen‐specific humoral immune response of animals to anti‐idiotypic antibodies and comparative serological analysis of patients with small‐cell lung carcinoma
Budisavljevic et al. Angiotensin II (AII)-related idiotypic network. II. Heterogeneity and fine specificity of AII internal images analyzed with monoclonal antibodies.
Rhodin et al. Characterization of the Streptococcus mutans P1 epitope recognized by immunomodulatory monoclonal antibody 6-11A
Senpuku et al. Identification of a repeated epitope recognized by human serum antibodies in a surface protein antigen of Streptococcus mutans
AU757334B2 (en) Specific binding proteins for treating canine allergy
PL175651B1 (pl) Antyidiotypowe mysie przeciwciała monoklonalne oraz sposób wytwarzania antyidiotypowych przeciwciał monoklonalnych
Ma et al. Functional mimicry of an anti‐idiotypic antibody to nominal antigen on cellular response
Rio et al. Idiotypic restriction of murine monoclonal antibodies to a defined antigenic region of human thyroglobulin
WO2001036485A3 (es) Anticuerpo monocolonal recombinante que reconoce el antigeno ior c2 su uso para el diagnostico y tratamiento de tumores colorectales
Bufe Significance of IgE-binding epitopes in allergic disease